Bio Product Guide » RNAi Technology

Alnylam Grants KOKEN License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market

Jim Marino — Tue, 03 Nov 2009 15:10:53 +0000

Alnylam Pharmaceuticals, Inc. and KOKEN Co.,Ltd., announced that Alnylam has granted KOKEN a non-exclusive worldwide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers fundamental aspects of the structure and uses of RNAi products, including small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells, and of RNAi-related mechanisms.

Alnylam to contribute over 1,500 RNAi patents

Jim Marino — Tue, 11 Aug 2009 10:54:52 +0000

Alnylam Pharmaceuticals would contribute over 1,500 RNA interference (RNAi) patents to the patent pool established by GlaxoSmithKline in March 2009. Alnylam is known for the development of therapeutics based on RNAi for the treatment of respiratory syncytial virus (RSV) infection, liver cancer, hypercholesterolemia, Huntington’s disease, and TTR amyloidosis. The patents in the pool will be provided on a royalty-free, non-profit basis in Least Developed Countries via licensing agreements with qualified third parties.

Next Generation RNAi Technology Discovered by AiRNA Pharmaceuticals and Boston Biomedical

Jim Marino — Fri, 02 Jan 2009 08:32:15 +0000

Boston Biomedical, Inc. and AiRNA Pharmaceuticals, Inc. have announced that asymmetrical interfering RNA (aiRNA), a new fundamental RNAi technology discovered by the companies, is being published in the December issue of Nature Biotechnology. The publication titled “Asymmetric RNA Duplexes Mediate RNA Interference in Mammalian Cells” highlights that the smaller 15 bp aiRNA can target a variety of genes with superior efficiency than the standard 19-21 bp siRNA. Furthermore, the new aiRNA structure can target genes more selectively with significantly less off-target effects than the standard 19-21 bp siRNA.

Invitrogen Launches In Vivo RNAi Delivery Reagent – Products To Simplify And Enable Research On All Sequencing Platforms

Jim Marino — Fri, 28 Nov 2008 09:10:04 +0000

Invitrogen Corporation production and diagnostics has announced the introduction of its Invivofectamine™ delivery reagent which enables short interference ribonucleic acid (siRNA) experiments in vivo. The study of RNA interference (RNAi) has revolutionized biology by allowing researchers to directly observe the effects of the loss of function of specific genes in mammalian systems. Using proprietary technology, the Invivofectamine™ delivery reagent allows researchers to directly study the effects of siRNA inside a living organism for a variety of applications, including the drug discovery process.

Researchers develop advanced delivery system

Jim Marino — Fri, 10 Oct 2008 13:32:26 +0000

Researchers at the University of Texas have developed a polymer-based delivery system which could lead to vaccines that would be more effective and specific to the infectious disease. The engineers have used ribonucleic acid (RNA) molecules for the purpose. The two year long study used the new system on mice, delivering a DNA-based hepatitis B vaccine. The immune response was found to be much stronger as compared to the conventional system.